Wedge Capital Management L L P NC Sells 8,048 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wedge Capital Management L L P NC trimmed its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 25.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,168 shares of the specialty pharmaceutical company's stock after selling 8,048 shares during the period. Wedge Capital Management L L P NC owned approximately 0.11% of ANI Pharmaceuticals worth $1,618,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after buying an additional 364 shares in the last quarter. Natixis Advisors LLC grew its position in ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after acquiring an additional 417 shares in the last quarter. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV increased its stake in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in ANI Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock valued at $630,000 after purchasing an additional 675 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Guggenheim reiterated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. HC Wainwright reissued a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Finally, Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $80.13.

Insider Activity

In other news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now directly owns 107,317 shares in the company, valued at approximately $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,281 shares of company stock valued at $322,306. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ:ANIP traded up $0.44 during midday trading on Friday, hitting $62.56. 150,686 shares of the stock traded hands, compared to its average volume of 310,620. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business's 50 day moving average is $64.74 and its two-hundred day moving average is $61.09. The stock has a market capitalization of $1.36 billion, a PE ratio of -113.75 and a beta of 0.55. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals's quarterly revenue was up 43.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.